ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
about
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentCIViC databaseAssociation studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).Germline pharmacogenetics of paclitaxel for cancer treatment.Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Drug transporters in breast cancer: response to anthracyclines and taxanes.FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment.
P2860
Q26749954-D9C69088-EC9B-45E1-A5D7-B3402037F3D9Q27612411-9A56C817-AE5F-4478-8CCE-B9DB24961C60Q27853035-5653139D-5A33-43EA-94F5-E4BA8ACD72E9Q36413979-E476365A-DFA5-4C57-BC2B-DA666CDB5884Q37709365-9DDA6316-FE5E-4E02-846C-73AA38C64399Q38120289-526F4A3D-F255-4D6E-A1C0-B5C26B53800FQ38377393-678D4AC1-75FF-4701-9A67-F90FFBB96F35Q38575008-0E66E296-B353-4E94-8551-8B26857C9D79Q42286703-22A2B416-FF89-4EB5-9DCE-3DEC2E39E4F3Q43466172-8BB2A2CA-E905-46C8-B826-DD640383BB98Q52599656-8CFEAC7A-6C81-49FA-917D-CAC096C2300A
P2860
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@ast
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@en
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@nl
type
label
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@ast
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@en
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@nl
prefLabel
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@ast
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@en
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@nl
P2093
P2860
P3181
P356
P1433
P1476
ABCB1, FCGR2A, and FCGR3A poly ...... plus trastuzumab chemotherapy.
@en
P2093
Do-Youn Oh
Hye-Suk Han
In Ae Park
Jee Hyun Kim
Ji-Won Kim
Jin-Soo Kim
Sae-Won Han
Seock-Ah Im
Tae-You Kim
Wonshik Han
P2860
P304
P3181
P356
10.1159/000341359
P577
2012-01-01T00:00:00Z